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Summary. Adrenocortical function was studied on
admission and during treatment in 57 newly-
diagnosed patients with pulmonary tuberculosis,
16 of whom were treated with a daily regimen
containing Rifampicin (R-7), 22 with a twice-
weekly regimen containing the same drug (R-Z)
and 19 with a daily regimen that did not contain
Rifampicin (NR-7). In patients on daily treatment
(R-7 and NR-7), there was a slight increase in
plasma cortisol at 1 week followed by a decline;
while the mean level at 4 weeks was similar to that
on admission in the R-7 patients, that in the NR-7
patients was significantly lower (P < 0.01). No
change was observed in the R-2 patients. A
positive response to tetracosactrin was observed in
the 7 R-7, 14 R-Z and 7 NR-7 patients on
admission and in 6, 14 and 14, respectively at 4
weeks. The increase in the proportion of positive
responders in the NH-7 patients was significant
(P = 0.05). On admission, the diurnal rhythm of
the release of cortisol, as assessed by changes in
salivary cortisol, was disturbed in the patients
with an evening rise in the cortisol levels; it had,
however, reverted to a near-normal pattern after 2
months of treatment in all 3 groups of patients.
Introduction
Tuberculosis is believed to be one of the
 important causes of adrenal insufficiency in man.
Investigations undertaken recently in patients
 with pulmonary tuberculosis at Tuberculosis
 Research Centre, Madras, had shown that the
plasma cortisol concentrations were high and
nearly 50% of the patients had a negative
response to tetracosactrin, suggesting a lack of
adrenal reserve (or functional adrenocortical
insufficiency) in these patients1. Further, the
diurnal rhythm of cortisol release was disturbed
in these patients, with an evening rise in cortisol
levels; the pattern of changes observed in saliva
was s imi lar  to that observed in plasma
(unpublished findings), though the concentrations
were much lower. Rifampicin is a known inducer
of the hepatic microsomal enzyme system and has
been shown to cause an enhanced clearance of
endogenous cortisol2 and also of exogenously
administered corticosteroids3,4,5,6. The occurrence
of acute adrenal crisis in patients on treatment
with drug regimens containing Rifampicin has
also been reported7,8. We, therefore, undertook
an investigation to study the effect of two
different rhythms of administration of Rifampicin
(daily and twice-weekly) on the response to
tetracosactrin (given on admission and after 4
weeks of treatment) and compared the findings
with those observed in patients who received a
daily regimen that did not contain the drug. The
diurnal rhythm of the release of cortisol, as
assessed by cortisol levels in saliva, was also
examined on admission and after 2 months of
treatment in all the 3 groups of patients. This
report presents the findings.
Material and Methods
Pa ients and treatment regimens: Sputum smear-
positive patients with pulmonary tuberculosis
were randomly allocated to one of the following
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regimens (during the initial intensive phase of 2
months) :
R-7: Rifampicin 450 mg plus Ethambutol 800 mg
plus Isoniazid 300 mg plus Pyrazinamide 1.5 g
daily.
R-2: Rifampicin 450 mg plus Ethambutol 1.6 g
plus isoniazid 600 mg plus Pyrazinamide 2.0 g
twice-weekly.
N R - 7 :  Same as  R -7  above ,  but  w i thout
Rifampicin.
None of the patients was diabetic or pregnant
or on any form of steroid treatment at the time of
the investigation.
Plasma cortisol and tetracosactrin stimulation test :
Blood was collected between 08:00 and 08:30
hours on admission and at 1, 2 and 4 weeks after
the start of treatment, and plasma cortisol
determined. The tetracosactrin stimulation test
was performed on admission and at 4 weeks. On
both occasions, blood was collected for the
determination of the basal plasma cortisol and at
½ hour  and  1  hour  a f te r  in t ramuscu lar
administration of 0.25 mg (about 24 units) of
tetracosactrin (kindly donated by Hindustan Ciba
Geigy Ltd). Plasma was separated and stored at
–20°C till assay.
The patients were classified as positive or
negative respondersto tetracosactrin, the
criterion for a positive response being an increase
in plasma cortisol of 200 nmol/l or more at ½
hour and 1 hour over the respective basal level1.
Diurnal variation of cortisol level : This was
studied from changes in salivary cortisol on
admission and at 2 months after the start of
treatment. Saliva was collected at 08:00 hour and
then at 2-hourly intervals up to 20:00 hour. The
saliva specimens were frozen (kept at -20°C)
overn ight .  They  were  then thawed and
centrifuged; the residue containing mucoproteins
was discarded and the clear supernatant stored at
-20°C till assay.
Plasma cortisol was determined by a standard
RIA technique employing commercially available
cortisol assay kit (Amersham International plc,
England), and salivary cortisol was estimated
according to a method, adapting these kits,
standardized at our Centre (unpublished).
Student’s t-test (paired and unpaired) was
employed for testing the difference between the
mean cortisol levels, the chi-square test with
Yates’ correction for continuity to test the
differences between the proportions in the
different treatment groups, and McNemar’s test
for test ing the dif ferences between the
proportions within the same group at different
time-points.
Results
A total of 61 patients (54 male, 7 female) was  
admitted to the study; of these, 17 were allocated
to the R-7 regimen, 23 to the R-2 regimen and 21
to the NR-7 regimen. Four patients (1 R-7, 1 R-2,
2 NR-7) were excluded from the analysis due to  
culture negativity on admission, inadequate (<
80%) chemotherapy or failure to attend on one 
or more of the designated test-days. The analysis
is herefore based on 57 patients (16 R-7,22 R-2,
19 NR-7). The culture grading for M. tuberculosis
on admission was 3 + (confluent growth) in 35
patien s, 2 + (> 100 colonies) in 19, 1 + (20-100
colonies) in 2 and less than 20 colonies in 1
patient.
Plasma cortisol levels :The mean basal plasma
cortisol levels (08:00 hour) in the 3 groups, on
admission and at 1, 2 and 4 weeks after the start
of treatment are presented in Table 1 and Figure
1. Th  mean values were similar in the 3 groups
on admission. In the R-7 patients, the mean
plasma cortisol at 1 week was about 24% higher
(P = 0.06) than on admission. Further treatment
caused a decrease in the levels and the mean
value at 4 weeks was about 14% less than that at 1
week, and similar to that on admission. In the
NR-7 patients too, the mean value at 1 week was
about 11% higher (P = 0.06) than that on
admission and further treatment caused a
decrease and the mean value at 4 weeks was
about 21% less than that at 1 week (P < 0.01);
th  difference between the mean values on
admission and at 4 weeks (12%) was also
significant (P < 0.01). There was practically no
change in the mean basal plasma cortisol values
at different weeks in the R-2 patients.
At 1 and 2 weeks, only the mean value in the
R-7 patients was significantly higher than that in
the R-2 patients (P = 0.01 and 0.04, respectively),
and at 4 weeks, only the mean value in the R-7
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Table. 1. Mean plasma cortisol levels on admission and
up to 4 weeks of treatment with daily (R-7) and twice-
weekly (R-2) regimens containing Rifampicin and a
 daily regimen without the drug (NR-7)
Mean ± standard deviation of
plasma cortisol values (nmol/l)
Group
On admission   1 week2 weeks 4 weeks
(0 week)
R-7 471 ± 173 582± 140 550 ± 101502 ± 130
(n = 16)
R-2 449 ± 132 455 ± 153 448 ± 186456 ± 138
(n=22)
NR-7 466 ± 153 516 ± 126 481 ± 136410 ± 142
(n= 19)
Fig. 1. Mean plasma cortisol levels (nmol/l) on
admission (0 week) and at 1, 2 and 4 weeks
after the start of treatment in R-7 ( •—• ),
R-2 ( | |—| | )  and NR-7 pat ients  (o—o).
Vertical bars indicate the standard error of the
mean.
patients was higher than that in the NR-7 patients
(P = 0.05).
Response to tetracosactrin : The response of
patients to tetracosactrin on admission and at 4
weeks after the start of treatment is given in
Table 2. On admission, 7 of 16 R-7, 14 of 22 R-2
and 7 of 19 NR-7 patients had a positive response
to tetracosactrin, the total number of patients
with a positive response being 28 (49%) of 57
patients. The proportion of positive responders
among the R-2 patients was higher than those in
the other two groups, the differences not being
significant. Among the R-7 patients, 4 were
positive and 7 negative responders both on
admission and at 4 weeks; 3 patients who had a
positive response initially became negative
responders and 2 who were negative responders
initially had a positive response at 4 weeks.
Among the R-2 patients, the classification did not
alter in 14 patients; of the remaining 8 patients, 4
who had a positive response initially became
negative responders and 4 who were negative
initially had a positive response at 4 weeks.
Among the NR-7 patients, the classification was
the same on admission and at 4 weeks in 10
patients; 8 patients who were initially negative
became positive responders, and 1 patient who
was initially positive became a negative responder
at the end of 4 weeks. The proportions of patients
with a positive response to tetracosactrin at 4
weeks were 6 of 16 R-7,14 of 22 R-2 and 14 of 19
NR-7 patients. The increase in the proportion of
positive responders at 4 weeks over that on
admission was significant in the NR-7 patients (P
= 0.05), and there was a suggestion that this
proportion was higher than that in the R-7
patients at 4 weeks (P = 0.07).
The association between sputum culture
grading for M. tuberculosis and plasma cortisol or
positive response to tetracosactrin on admission
in the 57 patients is presented in Table 3. The
mean plasma cortisol value in patients with a 3 +
grading was significantly higher than that in
patients with a grading of 2 + or less (P = 0.01).
The difference between the proportions of
positive responders among patients with a
grading of 3 + and 2 + or less was not significant.
Sputum became negative for M. tuberculosis n 5
of 16 R-7, 3 of 22 R-2 and 5 of 19 NR-7 patients
by 1 months. No significant associations were
observed between the bacteriological status at 1
months and plasma cortisol or the proportion of
positive responders to tetracosactrin at 4 weeks
(data not presented).
Dismal variation of salivary cortisol : The mean
salivary cortisol levels being similar in the R-7,
R-2 and NR-7 patients on admission and at 2
mo hs were, therefore, amalgamated for further
analysis. The mean salivary cortisol levels at the
different time-points during the 12-hour period of
collection on admission and at 2 months, together
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Table. 2. Response to tetracosactrin on admission and after 4 weeks of treatment with daily (R-7) and twice-weekly
(R-2) regimens of Rifampicin and a daily regimen not containing the drug (NR-7)
Response to
tetraco-
sactrin on
admission
(0 week)
Response to tetracosactrin at 4 weeks
R-7 R-2 NR-7
Positive Negative TotalPositve Negative TotalPositive Negative Total
Negative 2 7 9 4 4 8 8 4 12
Total 6 10 16 14 8 22 14 5 19
Table. 3. Mean plasma cortisol and number of patients
with positive response to tetracosactrin
according to sputum culture grading for
M. tuberculosis on admission
Culture No. of Mean plasma
grading patients   cortisol ± stan-
dard deviation
(nmol/l)
3+ 35 504 ± 143
2+ 19
1+ 2 393 ± 131
1-19
colonies 1
57 461 ± 149
Positive
response to
tetracosactrin
No. %
15 43
12
1 59
0
28 49
wi h the distribution curve for health subjects
from an earlier study are presented in Table 4
and Figure 2. On admission, there was a decline
in salivary cortisol between 08:00 and 18:00 hours
(P < 0.001) followed by an increase, and the
mean value at 20:00 hour was significantly higher
than that at 18:00 hour (P = 0.03). After 2
months of treatment, the mean cortisol levels at
the different time-points were significantly lower
than the corresponding values on admission
(P < 0.02). Further, there was a decrease in the
cortisol levels beyond 18:00 hour, and the mean
value at 20:00 hour was significantly lower than
those at 18:00 hour and 08:00 hour (P < 0.001 for
both). The pattern of change in salivary cortisol in
the patients at 2 months was fairly similar to that
observed in the healthy subjects.
Table. 4. Diurnal variation of salivary cortisol in healthy subjects, and on admission and at 2
months after the start of treatment in patients with pulmonary tuberculosis
Group Month
Mean ± standard deviation of salivary cortisol values
(nmol/l) at the following hours (clock time)
TB patients
(n=57)
Healthy
subjects
(n=6)
08:OO l0:00 12:00 14:00 16:00 18:00 20:00
0 18.2 19.2 15.8 15.7 11.1 11.1 13.2
± ± ± ± ± ± ±
12.7 14.6 13.1 8.6 9.1 10.9 12.3
2 13.9 11.2 10.6 12.0 7.1 7.1 5.4
± ± ±
5.7
± ±
5.7 6.3 4.3 4.5 4.3 2.8
8.1 6.2 8.5 6.7 5.0 3.8 3.7
± ± ± ± ± ± ±
4.1 3.4 2.3 2.6 2.4 1.8 1.4
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Fig. 2. Diurnal variation of salivary cortisol on
admission (O—O) and at 2 months after the
start of treatment ( •—• ) in patients with
pulmonary tuberculosis, and in healthy subjec s
from an earlier study (•—•). Vertical bars
indicate the standard error of the mean.
Discussion
Adrenocort ical  funct ion appears to be
compromised in patients with pulmonary
tuberculosis. Despite high plasma levels of
cortisol, nearly 50% of the patients are negative
responders to tetracosactrin, suggesting a lack of
adrenal reserve (or functional adrenocortical
 insufficiency). This inadequate response is not
due to the high basal levels, as the association
between the base-line levels and the increase at ½
hour and 1 hour was weak, the correlation co-
efficients being -0.64 at ½ hour and -0.45 at 1
hour. Further, the diurnal rhythm of cortisol
secretion is disturbed in these patients with an
evening rise in cortisol levels. These findings are
in close agreement with those reported earlier
from this Centre1.
Maximal induction of the hepatic microsomal
enzyme system is known to occur after about a
week of treatment with daily regimens containing
Rifampicin9,10 Hence, the systemic clearance of
cortisol would also be expected to be high at this
time. Our findings, however, show that there is a
slight increase in plasma cortisol at 1 week in
both the groups of patients who received daily
treatment (R-7 and NR-7). Wilkins et al8 have
observed that there is a swelling of the adrenals
soon after start of treatment, probably similar to
the paradoxical enlargement of tuberculous
lymph nodes and cerebral tuberculomas with the
initiation of chemotherapy11,12,13,14. It is not known
whether this enlargement of the adrenals is
accompanied with an increase in the activity of
the glands, and whether this is responsible for the
initial increase in plasma cortisol observed in our
study.
Plasma cortisol and adrenal function in
tuberculous patients are governed by the stress
due to the disease, and a possible damage to the
adrenals due to the tuberculous process. Hence,
treatment with effective anti-tuberculosis drugs
should result in a decrease in the circulating
plasma cortisol level and an increase in the
proportion of patients with a positive response to
tetracosactrin. Both these effects were seen in
patients who did not receive Rifampicin (NR-7);
however, in patients who received this drug (R-7
nd R-2), the plasma cortisol levels at 4 weeks
after the start of treatment were similar to those
on admission and no increase was observed in the
number of positive responders to tetracosactrin.
On the contrary, 7 of 21 patients (in both the R-7
and R-2 groups), who had a positive response
initially, became negative responders at 4 weeks
as against 1 of 7 patients in the NR-7 group.
Response to tetracosactrin, on admission and
during treatment in patients with tuberculosis has
been studied by 3 other groups of investigators.
Ellis and Tayoub15 observed that 55% of 41
Africa  Zulu patients had a sub-normal response
to tetracosactrin and that the improvement in the
response after 15 days of treatment was inferior
in patients who received Rifampicin as one of the
drugs than in those who did not. These authors
did not report on plasma cortisol levels. In a
recent report, Scott et al16 observed a negative
response to tetracosactrin in 4 of 18 British
patients on admission. All the patients were
treated with a dai ly regimen containing
Rifampicin, Isoniazid and Ethambutol and these
uthors have reported that the expected decrease
in plasma cortisol during treatment was not seen,
n observation similar to our study; of the 4
patients with a sub-normal response, 1 died
unexpectedly, 2 received steroids and 1 patient
had a pers istentsub-normal response to
tetracosactrin. In a study by Barnes et al17 i n
M lanesian patients, the proportion of those with
a sub-normal response to tetracosactrin (8% of
90 patients with pulmonary, mil iary or
26 G. RAGHUPATI SARMA ET AL
extrapulmonary tuberculosis) was much less than
that in our series, and this is most probably due to
difference in the definition employed to classify
the patients as positive or negative responders to
te t racosact r in1. Further, they observed a
significant decrease in plasma cortisol, 3-4 weeks
after the start of treatment with a regimen
containing daily Rifampicin in addition to
Isoniazid, Pyrazinamide and Streptomycin,
findings contrary to those reported in our study
and by Scott e  al16. The daily regimen employed
by us (R-7) was similar to that used by Barnes et
a l17, except that Streptomycin was replaced by
Ethambutol, and it seems unlikely that this single
change could be responsible for the different
findings.
Findings in this paper suggest that
Rifampicin, whether administered daily or twice-
weekly exerts a deleterious effect on the
adrenocortical function, in patients with
pulmonary tuberculosis. The mechanism of
action is not clear; the sustained high plasma
cortisol concentrations, even up to 4 weeks in
patients receiving Rifampicin, appear to go
against a mechanism involving a more rapid
systemic clearance of this hormone induced by
the drug. Earlier investigations had shown that
dexamethasonec a u s e s  a n appreciable
suppression of cortisol levels in patients with
pulmonary tuberculosis1. And this suggests that
the HPA axis is intact in these patients. As such, a
decrease in plasma cortisol caused by an increase
in its clearance would trigger the release of
ACTH by the pituitary resulting in an increase in
the secretion of cortisol by the adrenal cortex.
Whether formation of antibodies to Rifampicin
or other immunological reactions such as the
formation of immune complexes involving
mycobacterial antigens precipitated by the rapid
killing of the bacteria or the induction of auto-
immune antibodies against adrenocortical cells
are responsible, is a matter of conjecture. Several
drugs such as procainamide, hydrallazine,
methyldopa and pencillamine have been shown to
induce auto-immune disorders such as systemic
lupus erythematosis,myasthenia gravis,
haemolysis and hepatitis18 and Rifampicin has
been implicated in evoking pemphigus, an auto-
immune disease of the skin19.
The diurnal rhythm of cortisol secretion was
disturbed in the patients with an evening rise in
cortisol levels before the start of treatment. The
immune system is known to modulate adrenal
production of glucocorticoids and cortisol, in
turn, has been shown to regulate certain immune
responses. Monokines, particularly interleukin-1,
rel a ed by activated monocytes, are known to
stimulate the hypothalamus, the pituitary and the
adrenal cortex20,21,22. Stimulation of hypothalamus
would not only cause an increase in the release of
CRF, which would ultimately lead to an increase
in the cortisol production, but also of certain 
other factors such as PGE2 which cause a
elevation in body-temperature23. An evening rise 
in body-temperature is well-established in 
patients with tuberculosis, but the association
between the two phenomena pre-supposes a 
circadian rhythm in the release of monokines
also. The existence of such a rhythm of several
immune responses is now well-recognised. Thus,
cytolytic activity of natural killer cells24, mitogenic
and antigenic responses25,26,27,28, the counts of
eosinophils and neutrophils28 and of T and B cell
populations of human lymphocytes29,30 have been
shown to exhibit a circadian rhythm. The maximal
levels of T and B cells were attained at midnight
followed by a depression during the day, and Abo
et al have shown that variations in the cell
counts were inversely related with plasma cortisol
levels in healthy subjects.
The diurnal rhythm of cortisol secretion had 
reverted to a near-normal pattern after 2 months
of treatment in all the 3 groups of patients.
Response to tetracosactrin was not examined at
this time and whether this also returns to normal
in a majority of the patients with continued
treatment with regimens containing Rifampicin
remains to be investigated.
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